Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview

Aurinia Pharmaceuticals

27/07/2026 13:57

Aurinia Pharmaceuticals Inc AUPH.OQ AUPH.O is expected to  show a rise in quarterly revenue when it reports  results on July 29 (estimated) for the period ending June 30 2026
The Edmonton Alberta-based  company is expected to report a 13.8% increase in revenue to $79.697 million from $70.01 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Aurinia Pharmaceuticals Inc is for earnings of 24 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Aurinia Pharmaceuticals Inc is $17.00, about 10.7% above its last closing price of $15.35
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
0.21
0.20
0.25
Beat
26.3
Dec. 31 2026
0.22
0.22
0.26
Beat
20
Sep. 30 2025
0.16
0.16
0.23
Beat
43.8​
Jun. 30 2025
0.17
0.15
0.16
Beat
9.1
​​Mar. 31 2025
0.10
0.10
0.16
Beat
60
Dec. 31 2024
-0.01
-0.02
0.01
Beat
162.5​
Sep. 30 2024
0.02
0.02
0.10
Beat
566.7
Jun. 30 2024
0.01
0.01
0.01
Met
20
This summary was machine generated July 27 at 12:57 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)